Chromadex Corp
Change company Symbol lookup
Select an option...
CDXC Chromadex Corp
DPDW Deep Down Inc
WOLF Wolfspeed Inc
CNBP Cornerstone Bancorp Inc
UPS United Parcel Service Inc
RHHBY Roche Holding AG
EGP Eastgroup Properties Inc
PMT PennyMac Mortgage Investment Trust
GS Goldman Sachs Group Inc

Health Care : Life Sciences Tools & Services | Small Cap Growth
Company profile

ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Closing Price
Day's Change
0.05 (2.94%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
May 19, 2022
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the "JV Agreement") to establish a joint venture through its wholly owned subsidiary ChromaDex...(BusinessWire)

May 17, 2022
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen(R)

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP(TM)) with a 2022 European NutraIngredients Award in the "Nutrition...(BusinessWire)

May 12, 2022
ChromaDex Corporation Reports First Quarter 2022 Financial Results

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022. First Quarter 2022 and Recent Highlights Total net sales were $17.3 million, up 18% from the prior year quarter. Tru Niagen(R) net sales were $14.9...(BusinessWire)

April 29, 2022
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial results will be reported in a press...(BusinessWire)

April 22, 2022
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief...(BusinessWire)

April 14, 2022
ChromaDex External Research Program (CERP(TM)) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World

ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program (CERP(TM)), featuring ChromaDex's flagship ingredient Niagen(R) (patented nicotinamide riboside, or NR) and...(BusinessWire)

April 06, 2022
ChromaDex Launches Tru Niagen(R) Immune, Further Expanding Innovative Product Portfolio

ChromaDex Corp. (NASDAQ:CDXC) today announced the company's latest product innovation with the U.S. launch of Tru Niagen(R) Immune, a first-of-its-kind combination of ChromaDex's proprietary NAD-boosting ingredient Niagen(R) (patented nicotinamide...(BusinessWire)

March 16, 2022
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide...(BusinessWire)

March 09, 2022
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results. Fourth Quarter 2021 and Recent Highlights Total net sales were $17.8 million, up 15% year over year. Tru Niagen(R) net sales were $14.1 million, a...(BusinessWire)

March 02, 2022
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson's Disease (PD)

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.